Jang-June Park1, David K Wong2, Abdus S Wahed3, William M Lee4, Jordan J Feld2, Norah Terrault5, Mandana Khalili5, Richard K Sterling6, Kris V Kowdley7, Natalie Bzowej8, Daryl T Lau9, W Ray Kim10, Coleman Smith11, Robert L Carithers12, Keith W Torrey1, James W Keith1, Danielle L Levine1, Daniel Traum1, Suzanne Ho1, Mary E Valiga1, Geoffrey S Johnson3, Edward Doo13, Anna S F Lok14, Kyong-Mi Chang15. 1. Philadelphia Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 2. University of Toronto, Toronto, Ontario, Canada. 3. University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. 4. University of Texas Southwestern, Dallas, Texas. 5. University of California, San Francisco, San Francisco, California. 6. Virginia Commonwealth University, Richmond, Virginia. 7. Virginia Mason Medical Center, Seattle, Washington. 8. California Pacific Medical Center, San Francisco, California. 9. Beth Israel Deaconess Medical Center, Boston, Massachusetts. 10. Mayo Clinic, Rochester, Minnesota. 11. University of Minnesota, Minneapolis, Minnesota. 12. University of Washington Medical Center, Seattle, Washington. 13. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 14. University of Michigan, Ann Arbor, Michigan. 15. Philadelphia Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania; University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. Electronic address: kmchang@mail.med.upenn.edu.
Abstract
BACKGROUND & AIMS: T cells play a critical role in viral infection. We examined whether T-cell effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB). METHODS: We enrolled 200 adults with CHB who participated in the National Institutes of Health-supported Hepatitis B Research Network from 2011 through 2013 and 20 uninfected individuals (controls). Peripheral blood lymphocytes from these subjects were analyzed for T-cell responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolysaccharide. T-cell expression of regulatory markers FOXP3, programmed death-1, and cytotoxic T lymphocyte-associated antigen-4 was examined by flow cytometry. Immune measures were compared with clinical parameters, including physician-defined immune-active, immune-tolerant, or inactive CHB phenotypes, in a blinded fashion. RESULTS: Compared with controls, patients with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequency of circulating FOXP3(+)CD127(-) regulatory T cells and CD4(+) T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4. T-cell measures did not clearly distinguish between clinical CHB phenotypes, although the HBV core-specific T-cell response was weaker in hepatitis B e antigen (HBeAg)(+) than HBeAg(-) patients (percent responders: 3% vs 23%; P = .00008). Although in vitro blockade of programmed death-1 or cytotoxic T lymphocyte-associated antigen-4 increased T-cell responses to HBV, the effect was weaker in HBeAg(+) than HBeAg(-) patients. Furthermore, T-cell responses to influenza and lipopolysaccharide were weaker in CHB patients than controls. CONCLUSIONS: HBV persists with virus-specific and global T-cell dysfunction mediated by multiple regulatory mechanisms, including circulating HBeAg, but without distinct T-cell-based immune signatures for clinical phenotypes. These findings suggest additional T-cell-independent or regulatory mechanisms of CHB pathogenesis that warrant further investigation.
BACKGROUND & AIMS: T cells play a critical role in viral infection. We examined whether T-cell effector and regulatory responses can define clinical stages of chronic hepatitis B (CHB). METHODS: We enrolled 200 adults with CHB who participated in the National Institutes of Health-supported Hepatitis B Research Network from 2011 through 2013 and 20 uninfected individuals (controls). Peripheral blood lymphocytes from these subjects were analyzed for T-cell responses (proliferation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) peptides (preS, S, preC, core, and reverse transcriptase), influenza matrix peptides, and lipopolysaccharide. T-cell expression of regulatory markers FOXP3, programmed death-1, and cytotoxic T lymphocyte-associated antigen-4 was examined by flow cytometry. Immune measures were compared with clinical parameters, including physician-defined immune-active, immune-tolerant, or inactive CHB phenotypes, in a blinded fashion. RESULTS: Compared with controls, patients with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequency of circulating FOXP3(+)CD127(-) regulatory T cells and CD4(+) T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated antigen-4. T-cell measures did not clearly distinguish between clinical CHB phenotypes, although the HBV core-specific T-cell response was weaker in hepatitis B e antigen (HBeAg)(+) than HBeAg(-) patients (percent responders: 3% vs 23%; P = .00008). Although in vitro blockade of programmed death-1 or cytotoxic T lymphocyte-associated antigen-4 increased T-cell responses to HBV, the effect was weaker in HBeAg(+) than HBeAg(-) patients. Furthermore, T-cell responses to influenza and lipopolysaccharide were weaker in CHB patients than controls. CONCLUSIONS:HBV persists with virus-specific and global T-cell dysfunction mediated by multiple regulatory mechanisms, including circulating HBeAg, but without distinct T-cell-based immune signatures for clinical phenotypes. These findings suggest additional T-cell-independent or regulatory mechanisms of CHB pathogenesis that warrant further investigation.
Authors: Stefan F Wieland; Angelina Eustaquio; Christina Whitten-Bauer; Bryan Boyd; Francis V Chisari Journal: Proc Natl Acad Sci U S A Date: 2005-07-01 Impact factor: 11.205
Authors: Margaret Chen; Matti Sällberg; Janice Hughes; Joyce Jones; Luca G Guidotti; Francis V Chisari; Jean-Noel Billaud; David R Milich Journal: J Virol Date: 2005-03 Impact factor: 5.103
Authors: Hirotoshi Ebinuma; Nobuhiro Nakamoto; Yun Li; David A Price; Emma Gostick; Bruce L Levine; J Tobias; William W Kwok; Kyong-Mi Chang Journal: J Virol Date: 2008-03-12 Impact factor: 5.103
Authors: Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Benjamin Fram; Jeffrey S Glenn; David E Kleiner; Christopher Koh; Theo Heller Journal: J Gastroenterol Hepatol Date: 2019-02-25 Impact factor: 4.029
Authors: Marc G Ghany; Jordan J Feld; Kyong-Mi Chang; Henry L Y Chan; Anna S F Lok; Kumar Visvanathan; Harry L A Janssen Journal: Lancet Gastroenterol Hepatol Date: 2020-02-10
Authors: Timothy M Block; Stephen Locarnini; Brian J McMahon; Barbara Rehermann; Marion G Peters Journal: Clin Infect Dis Date: 2017-05-01 Impact factor: 9.079
Authors: Jessica P Hwang; Maria E Suarez-Almazor; Scott B Cantor; Andrea Barbo; Heather Y Lin; Sairah Ahmed; Mariana Chavez-MacGregor; Christian Donato-Santana; Cathy Eng; Alessandra Ferrajoli; Michael J Fisch; Peter McLaughlin; George R Simon; Gabriela Rondon; Elizabeth J Shpall; Anna S Lok Journal: Cancer Date: 2017-05-18 Impact factor: 6.860